MY-YD-01 raised detection of glaucoma-like damage on fundus photos

In Tencent's trial of 1,092 subjects that China's CMDE reviewed, the trial group's sensitivity for glaucoma-like optic nerve changes exceeded the control group's by 16.42%.

  • Not rated an organization

    Detection was measured in the maker's pre-market trial, and the report does not say that the prompts guided any patient's care.

Depth runs from 1, a convenience or time saved, to 5, a life or a livelihood preserved.

Status
Intended benefit.
Evidence

foundstudiedreportedclaimed

An independent regulatory document supports the benefit.

Compared with

The control group of the same trial (the report does not describe how either group read the photographs). Measured.

The system’s part
The controlled trial compared a trial group with a control group, and the report gives the software's own results separately, so the trial group presumably read with the software. The report does not describe either group, and the trial was the maker's own.
Not yet checked
LimitsCosts and harmsLearns from dataLater outcome

Download data Cite Suggest a correction

Benefit type
Improved Task Accuracy
System
MY-YD-01 (慢性青光眼样视神经病变眼底图像辅助诊断软件)
Made by
Tencent Healthcare (Shenzhen) Co., Ltd. (腾讯医疗健康（深圳）有限公司)
Used by
Tencent Healthcare (Shenzhen) (registration trial with 1,092 subjects at four institutions)
Where
Four trial institutions that the report does not name, for a registration in China
Stage
Tested in a laboratory
Date
, when the source was published
Kind
Aggregate result
Broad benefit
Identifying Objects, Actions, and Events, Analyzing Data or Information
Collections
Scrutiny and findings
Last revised
1 November 2026

Sources

  1. Regulatory document, by authors with no tie to the system.

    Center for Medical Device Evaluation (CMDE), National Medical Products Administration, China. 医疗器械产品注册技术审评报告：慢性青光眼样视神经病变眼底图像辅助诊断软件 (technical review report for the registration of fundus image diagnosis-aid software for chronic glaucoma-like optic neuropathy), acceptance no. CQZ2100700, applicant 腾讯医疗健康（深圳）有限公司. 29 August 2022. Section 三、临床评价概述 (clinical evaluation), p. 7.

    受试者水平检出灵敏度，FAS 及 PPS 集的试验组与对照组差值分别为16.42% （ 95%CI ： 3.09%-28.97% ） 和 18.97% （ 95%CI ：3.60%-33.08%） ，均满足优效性验证。
    根据申请人提供的申报资料，经综合评价，在目前认知水平上，认为该产品受益大于风险。

Details

AI system

Reported configuration

Release V1

Workflow

Deep learning modules checked image quality, segmented the optic disc and cup and classified each accepted photograph. The software fused the predictions of a disc-and-cup model and a whole-image model into one prompt.

Follow-up

Conditions for replication

Photographs are single non-mydriatic color fundus images of about 45 degrees from a specified camera that pass the software's quality check. Patients are adults, and people with high myopia are excluded. Doctors qualified for fundus examination make the decision and do not rely on the prompt alone.

Entry details

Sector

Healthcare.

Purpose

Tencent Healthcare (Shenzhen) built MY-YD-01 to flag suspected chronic glaucoma-like optic neuropathy on fundus photographs of adults and suggest whether they need further examination.

29 more questions not yet checked

model, provider, role, configuration, inputs and outputs, autonomy, human oversight, beneficiaries, reach, distribution and access, duration, every measurement question, every money question, ownership and control, dependencies, cross-border connections, geopolitical implications, replication attempts, availability, institutional decision, grounds, action and result, success criterion, every evidence question, observed or intended, alternative assessments, related entries, other identifiers, category mappings.

Cite this record

Peter H. Vartanian. (2026). MY-YD-01 raised detection of glaucoma-like damage on fundus photos (AIBD-1073). Artificial Intelligence Benefits Database, edition of 1 November 2026. https://petervartanian.xyz/aibd/records/AIBD-1073.html (archived at https://doi.org/10.7910/DVN/AADSII, version 7.0)

BibTeX Data Field definitions